Are you a small business owner or entrepreneur eager to strengthen your team and retain top talent? Join Innovate Carolina Junction on November 13 for an insightful workshop on employee retention ...

Gilero, a medical device manufacturer with two sites in North Carolina, is expanding to a third site in the state -- a new 60 ...

Reflect on your last visit to a healthcare provider. Did you feel like a valued partner in your care? Now, consider participating in a research study with an unapproved potential treatment. How has ...

Building the right leadership team is crucial for any startup looking to scale beyond proof-of-concept. This webinar will overview the complexities, strategy, and timing of hiring the right executive ...

The JPMorgan Healthcare Conference provides a platform for sharing stories, establishing meaningful connections, and managing time effectively. Learn how to navigate JPM with intentional networking ...

Paris-based biotechnology company Cellectis (NASDAQ: CLLS) has announced the first patient in the U.S. to receive a dose of its UCART22 allogeneic CAR T-cell therapy product candidate that was ...

The first-ever point-of-care instrument for qualitatively detecting fentanyl in human urine has been cleared for use by the U.S. Food Drug Administration and will be distributed in the United States ...

David Reeser is one of the millions of Americans whose life has been changed by the ever-evolving, fast-growing epidemic of ...

Charles E. Hamner, Jr., Ph.D., a former president and CEO of the North Carolina Biotechnology Center and a longtime advocate for life sciences in the state, has received the 2024 High Flyer Champion ...

The Triangle is known as a hotbed for innovation, thanks in large part to the partnerships between multiple stakeholders, including universities, investors and ecosystem support organizations. In that ...

Radiopharmaceuticals, once a very niche drug class, are now on the brink of transforming cancer treatment and diagnostics, and North Carolina is at the heart of this change. These radioactive drugs ...

Research Triangle Park-based Opus Genetics, a clinical-stage gene therapy company devoted to treating inherited retinal diseases, has been acquired by a small ophthalmic biopharmaceutical firm with ...